Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
Grant
Overview
Affiliation
Overview
Awarded By
National Marrow Donor Program
Total Award Amount
593008.00
Direct Costs
456160.00
Sponsor Award Id
Affiliation
Contributor
Racquel Innis-Shelton M.D.
Investigator